Advertisement

Hospital pharmacy news, drug costs and specialty pharmacy trends

Becker’s reports on drug prices, shortages and the specialty pharmacy programs health systems are building. Coverage extends to 340B policy, pharmacy staffing and the distribution models.



More in Pharmacy

CMS has finalized a 2027 outpatient payment rule that cuts Medicare payments for 340B-acquired drugs by roughly a third starting Jan. 1. Cancer programs at 340B hospitals, which administer many of the costliest Medicare Part B drugs, will feel the…

A federal judge dismissed Tampa (Fla.) General Hospital’s lawsuit against Eli Lilly over its 340B claims data requirement, ruling Nov. 18 that the hospital’s state-law claims cannot proceed in court and pointing to HHS’ administrative dispute process as an avenue…

North Chicago, Ill.-based AbbVie has entered a collaboration and option-to-license agreement with Cologne, Germany-based DISCO Pharmaceuticals to develop cancer therapies targeting solid tumors, DISCO announced Nov. 19. Under the agreement, DISCO will receive $40 million upfront and is eligible for…

The FDA has approved Lembaz (adrabetadex) injection, the first treatment shown to help patients with infantile-onset Niemann-Pick disease type C live longer. The drug is approved to reduce the risk of death in adult and pediatric patients who weigh at…

Bon Secours Mercy Health uses its pharmacy benefit manager only for claims processing and network access. Everything else it runs itself, including its formulary, network design and claims audits. The Cincinnati-based system manages pharmacy benefits for about 100,000 covered lives,…

Hospitals and health systems nationwide are seeking pharmacy leaders as the role expands amid drug pricing pressure, supply chain constraints and growing 340B oversight. Many organizations have sharpened their focus on pharmacy as a strategic lever — elevating its role…

The FDA is proposing to withdraw the liquid formulation of simvastatin, known as FloLipid, from the market after Salerno Pharmaceuticals failed to file required annual reports, according to a Nov. 18 notice in the Federal Register. The FDA annual reports…

BioLineRx has agreed to sell its rights to certain future royalties from its FDA-approved drug APHEXDA (motixafortide) to Soleus Capital for $5.6 million. Under the agreement, Soleus will acquire BioLineRx’s 14.4% royalty interest in future APHEXDA net sales. BioLineRx will…

Advertisement
Advertisement
Advertisement